Sylvia R. Wheeler
Investor Relations Contact bei RAPT THERAPEUTICS, INC.
Profil
Sylvia R.
Wheeler is currently the Director-West Coast Division at Advances In Kidney Disease & Health and the Investor Relations Contact at Rapt Therapeutics, Inc. Previously, she held positions such as Director-Corporate Communications at Cerus Corp., Coulter Pharmaceuticals, Inc., and Affymax, Inc. She was also the Senior Director-Corporate Communications at Assertio Therapeutics, Inc. and the Head-Investor Relations & Corporate Communications at OncoMed Pharmaceuticals, Inc. Additionally, she served as the Director-Corporate Relations & Planning at Connetics Corp.
and the VP-Investor Relations & Corporate Communications at Hyperion Therapeutics, Inc. She was the Senior VP-Investor Relations & Corporate Affairs at Aduro BioTech, Inc. and the VP-Investor Relations & Corporate Affairs at Relypsa, Inc. Furthermore, she was the Investor Contact Relations at Immune Design Corp.
Ms. Wheeler received her undergraduate degree from San Francisco State University and her MBA from the University of San Francisco.
Aktive Positionen von Sylvia R. Wheeler
| Unternehmen | Position | Beginn |
|---|---|---|
| RAPT THERAPEUTICS, INC. | Investor Relations Contact | - |
Advances In Kidney Disease & Health
 Advances In Kidney Disease & Health Miscellaneous Commercial ServicesCommercial Services Advances In Kidney Disease & Health provides awareness on kidney and urinary tract diseases. The organization helps to increase the availability of all organs for transplantation. The company was founded in 1950 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Sylvia R. Wheeler
| Unternehmen | Position | Ende |
|---|---|---|
| IMMUNE DESIGN CORP | Investor Relations Contact | 02.04.2019 |
| HYPERION THERAPEUTICS INC | Investor Relations Contact | 03.04.2014 |
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Public Communications Contact | 01.01.2007 |
| CERUS CORPORATION | Public Communications Contact | 01.01.2003 |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Public Communications Contact | 01.01.2000 |
Ausbildung von Sylvia R. Wheeler
| San Francisco State University | Undergraduate Degree |
| University of San Francisco | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| CERUS CORPORATION | Health Technology |
| AFFYMAX, INC. | Health Technology |
| RAPT THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Coulter Pharmaceuticals, Inc.
Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Connetics Corp.
 Connetics Corp. BiotechnologyHealth Technology Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
Hyperion Therapeutics, Inc.
 Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Advances In Kidney Disease & Health
Advances In Kidney Disease & Health Miscellaneous Commercial ServicesCommercial Services Advances In Kidney Disease & Health provides awareness on kidney and urinary tract diseases. The organization helps to increase the availability of all organs for transplantation. The company was founded in 1950 and is headquartered in New York, NY. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
